category title

point word

MAIN title

(Please enter details about the category. Below is an example post. Delete the content and add the desired content).

FONT SIZE : 18px  / FONT : noto sans avestan

font size : 16px / font : noto sans 

Since established in 2015, Prestige Biopharma Research Centre in Singapore has been focusing on the R&D of biosimilar pipeline, while overseeing Prestige Biopharma pipeline R&D.

Singapore Research Center covers 12 biosimilar pipeline from its early stage of cell line development to phase 1-3 clinical study. Our rich portfolio of biosimilars in various stages including HD201 trastuzumab under marketing authorisation review, HD204 bevacizumab in global Phase 3, PBP1502 adalimumab in Phase 1 and others, aims to provide affordable high-quality medicines to patients around the globe.

To date, Prestige Biopharma has developed biosimilars of high quality and strong cost competitiveness in expedited development programmes, with the aim of enhancing patient access to affordable treatments of critical diseases.